LEO 27847 - A Phase 1, Double-Blind, Placebo Controlled, Single and Multiple Oral Dose, Safety, Tolerability, Pharmacokinetic and Pharmacodynamic Study in Healthy Male Subjects
Latest Information Update: 28 Oct 2015
At a glance
- Drugs LEO 27847 (Primary)
- Indications Kidney disorders
- Focus Adverse reactions
- Sponsors LEO Pharma
- 05 May 2014 New trial record